Geltor has raised $114.3M in total across 4 funding rounds.
Geltor's investors include Hatteras Venture Partners, Mayfield, Morpheus Ventures, SOSV, Synthesis Capital, Wilbur-Ellis [Cavallo], FTW Ventures, M34 Capital, Redpoint Ventures, Stray Dog Capital.
Geltor is a biotechnology company specializing in biodesign, using precision fermentation and synthetic biology to produce animal-free, sustainable proteins like collagen and elastin for beauty, nutrition, food, and beverage industries.[1][2][3][7] It serves consumer packaged goods brands seeking ethically sourced, high-performance ingredients, solving the problem of animal-derived proteins (which dominate over 90% of the collagen market from slaughter byproducts) by offering scalable, GMO-free alternatives with superior biocompatibility, purity, and efficacy.[1][3][5] Geltor operates an "ingredients-as-a-service" platform, enabling tailored bioactive proteins, and has shown strong growth momentum: founded in 2015, it raised over $114 million across six rounds, including a $93.1 million Series B in 2024 led by CPT Capital, while scaling production 100x amid 25% global collagen demand growth.[2][7]
Geltor was founded in 2015 by Princeton graduates Alex Lorestani (CEO) and Nick Ouzounov (CTO), two friends driven by a passion to bridge biology, beauty, and design through sustainable protein innovation.[2][7] The idea emerged from recognizing the disconnect between consumer demand for ethical, effective ingredients and reliance on animal-sourced proteins like gelatin; they developed a recombinant platform for "real gelatin without the animal" using microbial fermentation.[1][6][7] Early traction came via collaboration with ABPDU (Advanced Biofuels and Bioproducts Development Unit), where as a Bay Area startup without its own lab, Geltor validated and scaled its animal-free collagen tech—testing bioreactors, improving oxygen transfer, and building a commercialization toolkit that set industry benchmarks.[4] Pivotal moments include launching HumaColl21® and Elastapure® (Elements of Skin™), gearing up for vegan collagen in 2021, and recent products like NuColl (2024) for hair and CAVIANCE™ (2023) for skin.[1][7]
Geltor's edge lies in its proprietary biodesign platform, which accelerates protein development from inspiration to market in months, not years, via a streamlined process:
This combination enables "designer proteins" for industries shifting from farm-to-lab.[1][5]
Geltor rides the synthetic biology and precision fermentation wave, transforming biotech into a programmable tool for sustainable ingredients amid rising ethical consumer demands and climate pressures on animal agriculture.[1][2][3] Timing is ideal: global collagen demand surged 25% yearly, fueled by clean-label trends in beauty (e.g., vegan skincare) and nutrition (e.g., ingestible proteins), while startups disrupt the $50B+ gelatin market dominated by slaughter byproducts.[1][2] Market forces like regulatory pushes for sustainability and CPG brands' net-zero goals favor Geltor's scalable, low-impact model, which intersects computational biology, fermentation, and biodesign to enable lab-to-table innovations like faux meats or spider silk.[1][4] It influences the ecosystem by proving biotech's cross-industry potential—partnering with facilities like ABPDU, inspiring pilot plants, and accelerating peers via shared scale-up learnings.[4][7]
Geltor is poised to dominate sustainable proteins, leveraging its platform for rapid expansion into food/beverage (e.g., NuColl scaling) and custom ingredients for brands, with funds fueling demand and a new pilot plant.[2][4][7] Trends like AI-driven biodesign, escalating ESG mandates, and precision fermentation cost drops will propel growth, potentially unlocking novel proteins for pharma or materials. Its influence may evolve from niche disruptor to supply-chain staple, redefining "conscious biodesign" as biotech's new standard—echoing its founding mission to make sustainable proteins ridiculously easy.[2][3]
Geltor has raised $114.3M across 4 funding rounds. Most recently, it raised $91.0M Series B in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2020 | $91.0M Series B | Hatteras Venture Partners, Mayfield, Morpheus Ventures, SOSV, Synthesis Capital, Wilbur-Ellis [Cavallo] | |
| Oct 1, 2018 | $18.0M Series A | Hatteras Venture Partners, Mayfield, Morpheus Ventures, SOSV | |
| Jan 1, 2016 | $5.0M Seed | FTW Ventures, Hatteras Venture Partners, M34 Capital, Mayfield, Morpheus Ventures, Redpoint Ventures, SOSV, Stray Dog Capital | |
| Sep 1, 2015 | $250K Seed | Hatteras Venture Partners, Mayfield, Morpheus Ventures, SOSV |
